Dr Gabriele Casirati speaks to ecancer about his study which showed that epitope editing enables targeted immunotherapy of acute myeloid leukaemia.
The study reported that tumour-associated antigens shared by normal tissue can be precisely modified, resulting in selective resistance to targeted immunotherapies and generating artificial leukaemia-restricted antigens.
The aim of this study was that high-risk patients who do not fare well with first-line treatments could receive an edited transplant, and after the transplant, they have the possibility to receive a very potent CART cell therapy without having the risk of on-target toxicity.
Dr Gabriele Casirati discusses the methodology and the results of the study in detail. He notes that epitope editing is a really promising new technology that can definitely be translated into clinical practice.
Read the full story here.